Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Price:
1.07 USD
-2.73%
Market Closed
Updated:
Apr 30, 2024
Section:
Relative Value
The Relative Value of one
RIGL
stock under the Base Case scenario is
3.87
USD.
Compared to the current market price of 1.07 USD,
Rigel Pharmaceuticals Inc
is
Undervalued by 72%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RIGL
Relative Value
Base Case
3.87
USD
Undervaluation 72%
Valuation Multiples
Multiples Across Competitors
RIGL Competitors Multiples
Rigel Pharmaceuticals Inc Competitors
Rigel Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
|
187.1m USD | 1.6 | -7.5 | -9.5 | -8.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.2B USD | 5.2 | 21.8 | 16.2 | 24.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102B USD | 10.3 | 28.2 | 22.5 | 23.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.7B USD | 7.4 | 24.7 | 16.3 | 18 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.2 | 35.3 | 21.4 | 26.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.9B USD | 3.1 | 14.6 | 8 | 10.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.4B USD | 6.2 | -9 | -9.5 | -8.1 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.2 | 27.2 | 14.7 | 18.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.1T KRW | 17.5 | 71.1 | 43.5 | 59.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
